0000899243-20-021565.txt : 20200805
0000899243-20-021565.hdr.sgml : 20200805
20200805194528
ACCESSION NUMBER: 0000899243-20-021565
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200803
FILED AS OF DATE: 20200805
DATE AS OF CHANGE: 20200805
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Turtle Cameron
CENTRAL INDEX KEY: 0001758363
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38533
FILM NUMBER: 201079305
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eidos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001731831
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463733671
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 650-391-9740
MAIL ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-03
0
0001731831
Eidos Therapeutics, Inc.
EIDX
0001758363
Turtle Cameron
C/O EIDOS THERAPEUTICS, INC.
101 MONTGOMERY STREET, SUITE 2000
SAN FRANCISCO
CA
94104
0
1
0
0
Chief Business Officer
Common Stock
2020-08-03
4
M
0
5000
13.20
A
80531
D
Common Stock
2020-08-03
4
S
0
2800
39.0471
D
77731
D
Common Stock
2020-08-03
4
S
0
6700
40.2495
D
71031
D
Common Stock
2020-08-03
4
S
0
500
40.8927
D
70531
D
Stock Option (Right to Buy)
13.20
2020-08-03
4
M
0
5000
0.00
D
2028-11-05
Common Stock
5000
80000
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2019.
Represents the weighted average sale price of the shares sold from $38.63 to $39.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 through 4.
Represents the weighted average sale price of the shares sold from $39.72 to $40.66 per share.
Represents the weighted average sale price of the shares sold from $40.80 to $41.018 per share.
25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
/s/ Franco Valle, as Attorney-in-Fact
2020-08-05